Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps

All NewsFebruary 20, 2026

Takeda shares are down slightly on Friday morning after positive Phase 3 Entyvio data show strong remission rates in ulcerative colitis trial.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent